An expert discusses how health plans evaluate high-cost NMIBC therapies by examining total cost of care, weighing risk versus reward for treatments like gene therapy that can cost over a million ...

This commentary argues that practitioners of cost-effectiveness analyses should incorporate dynamic drug pricing into formal cost-effectiveness analyses (CEAs). For reasons we discuss, doing so will ...

The draft assessment finds that the popular weight loss drugs are costly but worth the price tag, while also urging for ...

A new analysis from the Institute for Clinical and Economic Review has found that blockbuster GLP-1 drugs from Novo Nordisk and Eli Lilly offer substantial health benefits and are a cost-effective ...

Amid a yearslong wave of enthusiasm and uptake for Eli Lilly and Novo Nordisk's blockbuster obesity medicines, the drugs have scored a strong endorsement from an independent U.S. cost watchdog. | ICER ...

CKD screening at age 55, combined with SGLT2 inhibitors, reduces kidney failure incidence and improves life expectancy across racial and ethnic groups. Non-Hispanic Black adults experience the most ...